NKTX - Nkarta, Inc.
IEX Last Trade
2.415
0.005 0.207%
Share volume: 11,894
Last Updated: Thu 26 Dec 2024 08:26:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.41
0.00
0.21%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-6.00%
1 Month
-9.96%
3 Months
-48.69%
6 Months
-60.64%
1 Year
-55.07%
2 Year
-57.58%
Key data
Stock price
$2.42
DAY RANGE
$2.31 - $2.42
52 WEEK RANGE
$2.23 - $16.24
52 WEEK CHANGE
-$62.22
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Paul J. Hastings
Region: US
Website: nkartatx.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nkartatx.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.
Recent news